4.2 Article

Therapeutic implications of accurate classification of pituitary adenomas

Journal

SEMINARS IN DIAGNOSTIC PATHOLOGY
Volume 30, Issue 3, Pages 158-164

Publisher

W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1053/j.semdp.2013.06.002

Keywords

Pituitary adenoma; Classification; Pegvisomant; Temozolomide; Dopamine agonists; Somatostatin

Ask authors/readers for more resources

Recent data suggest that 1 of 5 individuals in the general population is affected with a pituitary adenoma. Many of these neoplasms are clinically non-functioning adenomas that may be small and clinically undetected or may present as mass lesions; others are hormonally active and cause significant morbidity due to the metabolic effects of hormone excess (e.g., acromegaly and cushing's disease). In either case, they can grow and invade adjacent anatomic structures. Tumors with similar clinical features are morphologically heterogenous and detailed comprehensive classification of pituitary adenomas is important to predict specific clinical behaviors and genetic changes that serve as targets for therapy. We provide a practical approach to clinical diagnosis and highlight the pitfalls in the classification of these common neoplasms. (C) 2013 Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available